Mustang Bio, Inc. (MBIO) financial statements (2021 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments98758556617383
Cash and cash equivalents98758556617383
Restricted cash and investments1   1  
Other undisclosed current assets1012121
Total current assets:100768658637483
Noncurrent Assets
Operating lease, right-of-use asset111111 
Property, plant and equipment8888877
Restricted cash and investments1111111
Other noncurrent assets0000000
Other undisclosed noncurrent assets      1
Total noncurrent assets:101011111099
TOTAL ASSETS:110869769738493
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9796665
Accounts payable43522  
Other undisclosed accounts payable and accrued liabilities5444465
Debt005320 
Due to related parties000110 
Other undisclosed current liabilities      1
Total current liabilities:1081510866
Noncurrent Liabilities
Long-term debt and lease obligation221113142 
Long-term debt, excluding current maturities  91112  
Operating lease, liability222222 
Other undisclosed noncurrent liabilities     1315
Total noncurrent liabilities:221113141515
Total liabilities:11102623222121
Stockholders' equity
Stockholders' equity attributable to parent98767146526271
Common stock0000000
Common stock, value, subscriptions80  5  
Additional paid in capital276241223183172172171
Accumulated deficit(185)(165)(152)(137)(125)(109)(99)
Total stockholders' equity:98767146526271
TOTAL LIABILITIES AND EQUITY:110869769738493

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(21)(10)(14)(12)(16)(10)(10)
Operating loss:(21)(10)(14)(12)(16)(10)(10)
Nonoperating income (expense)0(3)(0)(0)(0)(0)(0)
Interest and debt expense(0)(3)(1)(1)(1)(1)(1)
Net loss:(21)(16)(15)(12)(17)(11)(11)
Other undisclosed net income attributable to parent0311111
Net loss available to common stockholders, diluted:(21)(13)(15)(12)(16)(10)(10)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(21)(16)(15)(12)(17)(11)(11)
Comprehensive loss, net of tax, attributable to parent:(21)(16)(15)(12)(17)(11)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: